---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-026119"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2022-09-16T23:59:59+00:00"
generated_at: "2026-06-23T09:08:37.131021+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences CMO Dr. Nily Osman resigns; Dr. William Schmidt appointed interim CMO

## Summary
- Dr. Nily Osman resigned as Chief Medical Officer effective September 15, 2022.
- Dr. William K. Schmidt appointed interim Chief Medical Officer effective same date; he previously served as CMO from Jan 2016 to Apr 2022.
- Dr. Schmidt has over 25 years of pharma experience and led clinical development for Entereg (alvimopan) at Adolor Corporation.

## SEC filing metadata
- accession: 0001493152-22-026119
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2022-09-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/0001493152-22-026119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-026119
- JSON: https://secwatch.observer/filing/0001493152-22-026119.json
- Plain text: https://secwatch.observer/filing/0001493152-22-026119.txt

## Key facts
- Executive change
  Dr. William K. Schmidt was appointed as interim Chief Medical Officer at Ensysce Biosciences, Inc..
  - Action: appointed
  - Role: interim Chief Medical Officer
  source text: The Company has appointed Dr. William K. Schmidt, Ph.D. as the Company's interim Chief Medical Officer, effective as of September 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/0001493152-22-026119-index.htm
- Executive change
  Dr. Nily Osman resigned as Chief Medical Officer at Ensysce Biosciences, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: tender of resignation from its Chief Medical Officer, Dr. Nily Osman, such resignation effective as of September 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/0001493152-22-026119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.